Inaccuracy of a "spiked curve" for monitoring unfractionated heparin therapy

American Journal of Clinical Pathology

Volumn 135, Issue 6, 2011, Pages 870-876

  Gausman, Jana N ^a   Marlar, Richard A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Activated partial thromboplastin time; Anticoagulation; APTT; Monitoring; Unfractionated heparin

Indexed keywords

HEPARIN;

ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG MONITORING; EX VIVO STUDY; HEPARINIZATION; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

ANTICOAGULANTS; HEPARIN; HUMANS; PARTIAL THROMBOPLASTIN TIME; REPRODUCIBILITY OF RESULTS;

EID: 79957742888     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP60ZGXCJKRMJO     Document Type: Article

References (18)

1. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 suppl):141S-159S.
2. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992;152;1589-1594.
3. Cuker A, Ptashkin B, Konkle BA, et al. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti - factor Xa - correlated activated partial thromboplastin time. J Thromb Haemost. 2009;7:80-86.
4. Francis JL, Groce JB III; Heparin Consensus Group. Challenges in variation and responsiveness of unfractionated heparin. Pharmacotherapy. 2004;24(8 pt 2):108S-119S.
5. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med. 1993;119:104-109. (Pubitemid 23286474)
6. Clinical and Laboratory Standards Institute. On-stage prothrombin time (PT) test and activated partial thromboplastin time (APTT) test; 2nd edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. Document H47-A2.
7. Kitchen S, Preston FE. The therapeutic range of heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost. 1996;75:734-739. (Pubitemid 26181542)
8. Scialla SJ. Heparin monitoring by activated partial thromboplastin time. Am J Clin Pathol. 1985;84:351-354.
9. Bain B, Forster T, Sleigh B. Heparin and the activated partial thromboplastin time: a difference between the in vitro and in vivo effects and implications for the therapeutic range. Am J Clin Pathol. 1980;74:668-673. (Pubitemid 11241035)
10. Rosborough TK. Comparing different lots of activated partial thromboplastin time reagent: analysis of two methods. Am J Clin Pathol. 1998;110:173-177. (Pubitemid 28357655)
11. Marlar RA, Potts RM, Marlar AA. Effect on routine and special coagulation testing values of citrate anticoagulant adjustment in patients with high hematocrit values. Am J Clin Pathol. 2006;126:400-405. (Pubitemid 44338792)
12. Kitchen S, Theaker J, Preston FE. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis. 2000;11:137-144. (Pubitemid 30212853)
13. Hirsh J, van Aken WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 1976;53:691-695.
14. Chiu HM, Hirsh J, Yung WL, et al. Relationship between anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood. 1977;49:177-184.
15. Young E, Prins M, Levine MN, et al. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 1992;67:639-643.
16. Van den Besselaar AM, Meeuwisse-Braun J, Jansen-Gruter R, et al. Monitoring heparin therapy by the activated partial thromboplastin time: the effect of pre-analytical conditions. Thromb Haemost. 1987;57:226-231. (Pubitemid 18024517)
17. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122:782-788.
18. Olson JD. How to validate heparin sensitivity of the aPTT. CAP Today. 2004;18:72-78.